| |
| |
|
| Insider
Information: |
Paul Steven M |
| Relationship: |
|
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
6 |
|
| Direct
Shares |
1,185,025 |
|
|
Indirect Shares
|
632,151 |
|
|
| Direct
Value |
$36,994,095 |
|
|
|
Indirect Value
|
$29,510,726 |
|
|
| Total
Shares |
1,817,176 |
|
|
| Total
Value |
$66,504,822 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Eli Lilly & Co |
LLY |
EVP, Science and Techn... |
2010-02-01 |
38,897 |
2010-02-01 |
39,040 |
Premium* |
|
|
Sigma-Aldrich Corp |
SIAL |
Director |
2015-11-18 |
0 |
2007-01-02 |
0 |
Premium* |
|
|
Sage Therapeutics, Inc. |
SAGE |
|
2019-03-21 |
272,777 |
2022-11-28 |
593,111 |
Premium* |
|
|
Alnylam Pharmaceuticals Inc |
ALNY |
Director |
2022-04-01 |
1,000 |
2015-01-26 |
0 |
Premium* |
|
|
Voyager Therapeutics, Inc. |
VYGR |
President and CEO, Dir... |
2016-01-14 |
872,351 |
|
0 |
Premium* |
|
|
Karuna Therapeutics, Inc. |
KRTX |
|
2024-03-18 |
0 |
2024-03-18 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
131 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ALNY |
Alnylam Pharmaceuticals I... |
Director |
– • – |
2015-01-26 |
4 |
B |
$95.00 |
$95,000 |
D/D |
1,000 |
1,000 |
2.39 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Director |
– • – |
2020-02-10 |
4 |
AS |
$130.00 |
$3,900,000 |
D/D |
(30,000) |
1,000 |
0 |
% |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Director |
– • – |
2020-02-10 |
4 |
OE |
$14.67 |
$440,100 |
D/D |
30,000 |
31,000 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Director |
– • – |
2020-12-18 |
4 |
AS |
$140.00 |
$2,100,000 |
D/D |
(15,000) |
1,000 |
0 |
% |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Director |
– • – |
2020-12-18 |
4 |
OE |
$9.30 |
$139,500 |
D/D |
15,000 |
16,000 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Director |
– • – |
2022-04-01 |
4 |
AS |
$166.04 |
$2,560,371 |
D/D |
(15,000) |
1,000 |
0 |
% |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Director |
– • – |
2022-04-01 |
4 |
OE |
$11.33 |
$169,950 |
D/D |
15,000 |
16,000 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and TechnologyOff |
• – – |
2003-07-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
42,150 |
|
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and TechnologyOff |
• – – |
2003-07-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
20,504 |
|
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2003-08-05 |
4 |
S |
$64.87 |
$648,716 |
I/I |
(10,000) |
28,877 |
|
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2003-12-16 |
5 |
GD |
$0.00 |
$0 |
I/I |
216 |
28,661 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2003-12-17 |
5 |
GD |
$0.00 |
$0 |
I/I |
213 |
28,448 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2004-04-13 |
5 |
GD |
$0.00 |
$0 |
I/I |
109 |
38,843 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2004-06-02 |
5 |
GD |
$0.00 |
$0 |
D/D |
1,383 |
18,931 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2004-06-02 |
5 |
GA |
$0.00 |
$0 |
I/I |
1,383 |
40,226 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2004-06-02 |
5 |
D |
$74.74 |
$46,115 |
D/D |
(617) |
18,314 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2004-09-27 |
5 |
GA |
$0.00 |
$0 |
I/I |
10,314 |
50,540 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2004-09-27 |
4 |
OE |
$14.66 |
$274,095 |
D/D |
18,700 |
39,204 |
|
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2004-09-27 |
5 |
GD |
$0.00 |
$0 |
D/D |
10,314 |
8,000 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2004-09-27 |
4 |
D |
$63.66 |
$533,853 |
D/D |
(8,386) |
30,818 |
|
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2004-12-28 |
5 |
GD |
$0.00 |
$0 |
I/I |
234 |
50,306 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2005-01-14 |
4 |
A |
$56.79 |
$511,110 |
D/D |
9,000 |
39,818 |
|
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2005-05-26 |
4 |
GD |
$0.00 |
$0 |
D/D |
86 |
16,914 |
|
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2005-07-28 |
4 |
GD |
$0.00 |
$0 |
D/D |
87 |
16,827 |
|
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2005-10-13 |
4 |
OE |
$23.41 |
$99,997 |
D/D |
4,272 |
21,099 |
|
- |
|
131 Records found
|
|
Page 1 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
